Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study

Edoardo Biancalana,1,* Martina Chiriacò,1,* Paolo Sciarrone,1 Alessandro Mengozzi,1 Sandra Mechelli,2 Stefano Taddei,1 Anna Solini3 1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 2Section of General Medicine IV AUOP, University of Pisa, Pisa, Italy; 3D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Biancalana E, Chiriacò M, Sciarrone P, Mengozzi A, Mechelli S, Taddei S, Solini A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	remdesivir sars cov2 glomerular filtration rate aging chronic kidney disease Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/21676d37c97149749a241b7d6ff230e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:21676d37c97149749a241b7d6ff230e1
record_format	dspace
spelling	oai:doaj.org-article:21676d37c97149749a241b7d6ff230e12021-12-02T14:54:17ZRemdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study1178-1998https://doaj.org/article/21676d37c97149749a241b7d6ff230e12021-06-01T00:00:00Zhttps://www.dovepress.com/remdesivir-renal-function-and-short-term-clinical-outcomes-in-elderly--peer-reviewed-fulltext-article-CIAhttps://doaj.org/toc/1178-1998Edoardo Biancalana,1,* Martina Chiriacò,1,* Paolo Sciarrone,1 Alessandro Mengozzi,1 Sandra Mechelli,2 Stefano Taddei,1 Anna Solini3 1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 2Section of General Medicine IV AUOP, University of Pisa, Pisa, Italy; 3Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy*These authors contributed equally to this workCorrespondence: Anna SoliniDepartment of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, I-56126, ItalyTel +39-050993482Fax +39-050553235Email anna.solini@med.unipi.itBackground: Remdesivir, an antiviral agent able to reduce inflammatory cascade accompanying severe, life-threatening pneumonia, became the first drug approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus 2 related severe acute respiratory syndrome (SARS CoV2). As from its previously known clinical indications, the use of remdesivir in the presence of severe renal impairment is contraindicated; however, the impact of remdesivir on renal function in aging patients has not been elucidated.Subjects and Methods: This retrospective observational study involved 109 individuals consecutively admitted in internal medicine section, Azienda Ospedaliero Universitaria Pisana hospital, in November–December 2020 due to a confirmed diagnosis of SARS CoV2 and receiving remdesivir according to international inclusion criteria. Biochemical variables at admission were evaluated, together with slopes of estimated glomerular filtration rate (eGFR) built during remdesivir treatment. Participants were followed until discharge or exitus.Results: Patients were stratified according to age (80 formed the study cohort and 29 served as controls); CKD stage III was present in 46% of them. No patients showed any sign of deteriorated renal function during remdesivir. Fourteen patients in the elderly cohort deceased; their eGFR at baseline was significantly lower. Recovered patients were characterized by a relevant eGFR gaining during remdesivir treatment.Conclusion: We show here for the first time as remdesivir does not influence eGFR in a cohort of elderly people hospitalized for SARS CoV2, and that eGFR gain during such treatment is coupled with a better prognosis.Keywords: remdesivir, SARS CoV2, glomerular filtration rate, aging, chronic kidney diseaseBiancalana EChiriacò MSciarrone PMengozzi AMechelli STaddei SSolini ADove Medical Pressarticleremdesivirsars cov2glomerular filtration rateagingchronic kidney diseaseGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 16, Pp 1037-1046 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	remdesivir sars cov2 glomerular filtration rate aging chronic kidney disease Geriatrics RC952-954.6
spellingShingle	remdesivir sars cov2 glomerular filtration rate aging chronic kidney disease Geriatrics RC952-954.6 Biancalana E Chiriacò M Sciarrone P Mengozzi A Mechelli S Taddei S Solini A Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study
description	Edoardo Biancalana,1,* Martina Chiriacò,1,* Paolo Sciarrone,1 Alessandro Mengozzi,1 Sandra Mechelli,2 Stefano Taddei,1 Anna Solini3 1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 2Section of General Medicine IV AUOP, University of Pisa, Pisa, Italy; 3Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy*These authors contributed equally to this workCorrespondence: Anna SoliniDepartment of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, I-56126, ItalyTel +39-050993482Fax +39-050553235Email anna.solini@med.unipi.itBackground: Remdesivir, an antiviral agent able to reduce inflammatory cascade accompanying severe, life-threatening pneumonia, became the first drug approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus 2 related severe acute respiratory syndrome (SARS CoV2). As from its previously known clinical indications, the use of remdesivir in the presence of severe renal impairment is contraindicated; however, the impact of remdesivir on renal function in aging patients has not been elucidated.Subjects and Methods: This retrospective observational study involved 109 individuals consecutively admitted in internal medicine section, Azienda Ospedaliero Universitaria Pisana hospital, in November–December 2020 due to a confirmed diagnosis of SARS CoV2 and receiving remdesivir according to international inclusion criteria. Biochemical variables at admission were evaluated, together with slopes of estimated glomerular filtration rate (eGFR) built during remdesivir treatment. Participants were followed until discharge or exitus.Results: Patients were stratified according to age (80 formed the study cohort and 29 served as controls); CKD stage III was present in 46% of them. No patients showed any sign of deteriorated renal function during remdesivir. Fourteen patients in the elderly cohort deceased; their eGFR at baseline was significantly lower. Recovered patients were characterized by a relevant eGFR gaining during remdesivir treatment.Conclusion: We show here for the first time as remdesivir does not influence eGFR in a cohort of elderly people hospitalized for SARS CoV2, and that eGFR gain during such treatment is coupled with a better prognosis.Keywords: remdesivir, SARS CoV2, glomerular filtration rate, aging, chronic kidney disease
format	article
author	Biancalana E Chiriacò M Sciarrone P Mengozzi A Mechelli S Taddei S Solini A
author_facet	Biancalana E Chiriacò M Sciarrone P Mengozzi A Mechelli S Taddei S Solini A
author_sort	Biancalana E
title	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study
title_short	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study
title_full	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study
title_fullStr	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study
title_full_unstemmed	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study
title_sort	remdesivir, renal function and short-term clinical outcomes in elderly covid-19 pneumonia patients: a single-centre study
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/21676d37c97149749a241b7d6ff230e1
work_keys_str_mv	AT biancalanae remdesivirrenalfunctionandshorttermclinicaloutcomesinelderlycovid19pneumoniapatientsasinglecentrestudy AT chiriacom remdesivirrenalfunctionandshorttermclinicaloutcomesinelderlycovid19pneumoniapatientsasinglecentrestudy AT sciarronep remdesivirrenalfunctionandshorttermclinicaloutcomesinelderlycovid19pneumoniapatientsasinglecentrestudy AT mengozzia remdesivirrenalfunctionandshorttermclinicaloutcomesinelderlycovid19pneumoniapatientsasinglecentrestudy AT mechellis remdesivirrenalfunctionandshorttermclinicaloutcomesinelderlycovid19pneumoniapatientsasinglecentrestudy AT taddeis remdesivirrenalfunctionandshorttermclinicaloutcomesinelderlycovid19pneumoniapatientsasinglecentrestudy AT solinia remdesivirrenalfunctionandshorttermclinicaloutcomesinelderlycovid19pneumoniapatientsasinglecentrestudy
_version_	1718389370483900416

Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study

Ejemplares similares